How Hepatitis B and Delta Viruses Establish Infection of Liver Cells


Princeton University researchers have developed a new, scalable cell culture system that allows for detailed investigation of how host cells respond to infection with hepatitis B (HBV) and delta virus (HDV). The paper describing their findings was published online on June 18, 2019 in the journal Hepatology.

HBV causes an acute illness that is usually rapidly cleared by adults with intact immune systems, but young children and people with HIV are at particular risk of chronic HBV infection, which can lead to cirrhosis or cancer of the liver. Infection with HBV also renders a person vulnerable to infection with HDV, which can cause acute liver failure and/or accelerate the progression to cirrhosis or cancer. Fortunately, an effective vaccine exists for HBV, and because HDV requires HBV in order to reproduce, both can be considered preventable diseases. However, the expense and limited availability of the vaccine leaves millions at risk for infection worldwide.

A better understanding of how the viruses affect the cells they infect would assist in the development of drugs to combat or even cure infection, but HBV and HDV only infect liver cells (hepatocytes) from humans and chimpanzees. Such cells are difficult to obtain, and when grown outside the body in cell culture, they undergo a process called de-differentiation: over the course of just a few days, they lose their specialized characteristics and functionality. When this happens, they also lose the ability to be infected with HBV and HDV, creating a significant obstacle to studying chronic viral infection.

"Attempts have been made since the mid-1980s to establish robust - and, importantly, persistent - infection in primary human hepatocytes (PHHs) with limited success," said Alexander Ploss, an associate professor in the Department of Molecular Biology at Princeton and leader of the study.

Studies with other tissues have shown that specialized cell types sometimes require the support of other types of cells in order to maintain their differentiated status. Hepatocytes make up the majority of cells in the liver, but the tissue also contains many other cell types, which are collectively referred to as "non-parenchymal cells." Recently, graduate student Benjamin Winer, together with colleagues in Ploss' lab and at the Hurel Corporation, demonstrated that freshly isolated human hepatocytes can be grown together with non-parenchymal cells on a supporting surface made of collagen. In this cell culture system, which the researchers call a self-assembling co-culture of primary human hepatocytes (SACC-PHH), the hepatocytes retain their differentiated state and can support chronic HBV infection for up to 40 days.

"This system has created unprecedented opportunities to study host responses to hepatitis virus, especially in the context of persistent infection," Ploss said.

In the new study, Winer and colleagues investigated how hepatocytes respond to infection with HBV and HDV. First, they tested whether SACC-PHH can support infection with both viruses. HBV hijacks the cell's protein-making machinery to make viral proteins, and HDV co-opts HBV proteins to assemble itself. Therefore, HDV can only reproduce when it infects cells at the same time as HBV (co-infection) or in cells already chronically infected with HBV (super-infection). The researchers found that both of these scenarios can occur in SACC-PHH, even when the culture system has been scaled down to tiny 384 microwell culture plates -- a development that makes the system well suited for high-throughput screening of candidate drugs. Accordingly, the team showed that prophylactic treatment with two candidate antivirals, entecavir and Myrcludex B, could reduce levels of both hepatitis viruses in SACC-PHH.

Viral infection provokes many changes in the host cell, ranging from metabolic adaptations to the activation of innate immune defenses that can recognize and destroy a virus inside the cell. To explore what changes hepatocytes experience in response to HBV/HDV infection, the authors looked at which genes were being expressed using a technique called RNA-Seq analysis. The data showed that cells infected with HBV exhibit elevated expression of genes involved in oxidative phosphorylation and interaction with the extracellular environment. By contrast, cells additionally infected with HDV had similar gene expression patterns as uninfected cells.

Interestingly, even though the hepatocytes' innate immune signaling pathways were intact and could be stimulated by addition of chemicals such as poly(I:C), HBV infection did not activate these defenses. On the other hand, treatment with poly(I:C) helped suppress HBV growth, suggesting the virus flies under the radar of cells' defenses to establish persistent infection.

How innate immune defenses affect HBV/HDV co-infection appears more nuanced. Stimulation of innate immune pathways with poly(I:C) had little effect on HDV. HBV/HDV co-infection also failed to activate defense pathways in the hepatocytes of most human donors studied, but one donor showed innate immune activation upon co-infection, indicating a person's genetic makeup may influence their ability to combat the infection.

"We believe that our optimized, high-throughput SACC-PHH platform is a unique resource for investigating hepatotropic pathogens, and that our data will help advance understanding persistent infections by HBV and HDV," Ploss said.

The study was funded by the National Institutes of Health, the Burroughs Wellcome Fund, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, and the New Jersey Commission on Cancer Research.

The study, " Analysis of host responses to hepatitis B and delta viral infections in a microscalable hepatic coculture system," by Benjamin Y. Winer, Jenna M. Gaska, Gabriel Lipkowitz, Yaron Bram, Amit Parekh, Lance Parsons, Robert Leach, Rohit Jindal, Cheul H. Cho, Anil Shrirao, Eric Novik, Robert E. Schwartz and Alexander Ploss, was published online in the journal Hepatology on June 18, 2019.
Source: Princeton University 

Recent Videos
Andrea Flinchum, 2024 president of the Certification Board of Infection Control and Epidemiology, Inc (CBIC) explains the AL-CIP Certification at APIC24
Association for Professionals in Infection Control and Epidemiology  (Image credit: APIC)
Lila Price, CRCST, CER, CHL, the interim manager for HealthTrust Workforce Solutions; and Dannie O. Smith III, BSc, CSPDT, CRCST, CHL, CIS, CER, founder of Surgicaltrey, LLC, and a central processing educator for Valley Health System
Jill Holdsworth, MS, CIC, FAPIC, CRCST, NREMT, CHL
Jill Holdsworth, MS, CIC, FAPIC, CRCSR, NREMT, CHL, and Katie Belski, BSHCA, CRCST, CHL, CIS
Baby visiting a pediatric facility  (Adobe Stock 448959249 by
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Related Content